Is Novelix Pharma. overvalued or undervalued?

As of 18 November 2025, the valuation grade for Novelix Pharma has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 113.53, an EV to EBITDA of 80.00, and a Price to Book Value of 4.21. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Novelix Pharma's valuation stands out starkly; for instance, Sun Pharma has a PE ratio of 36.56 and an EV to EBITDA of 24.14, while Divi's Lab shows a PE of 69.17 and an EV to EBITDA of 51.98. The substantial differences in these ratios highlight that Novelix Pharma is significantly more expensive than its competitors. Furthermore, the company's recent stock performance has outpaced the Sensex, with a remarkable 1-year return of 190.52% compared to the Sensex's 9.48%, which may have contributed to its inflated valuation.